Login / Signup

Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.

Tessa G SteenbruggenMaartje van SeijenLiselore M JanssenMette S van RamshorstErik D van WerkhovenMarie-Jeanne T D F Vrancken PeetersJelle WesselingEsther H LipsGabe S Sonke
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
The RCB, NRI, and Neo-Bioscore can identify patients with HER2-positive breast cancer with minimal residual disease (i.e., RCB = 1, NRI ≥ 0.75, or Neo-Bioscore = 0-1) after NST who have similar 5-year RFI compared with patients with pCR.
Keyphrases
  • positive breast cancer
  • rectal cancer
  • locally advanced
  • lymph node
  • papillary thyroid
  • squamous cell carcinoma
  • radiation therapy
  • stem cells
  • mesenchymal stem cells
  • bone marrow